Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by Eskimomanon Feb 11, 2021 9:55pm
202 Views
Post# 32548856

RE:How do psychedelic companies make money?

RE:How do psychedelic companies make money?......I look at it this way and i am probably way over simplifying it...but in some ways you have answered your own question imo.....i brake it down to three catagories........the companies doing the research/clinical trials.....like Mindmed, Compass, Cybin,Tryp, etc.....thoes type of companies have zero revenue and will need millions to keep going......the next would be the ones doing research and are are actually operating a treatment clinic...like Numiness, Field Trip.....they have revenue and plan on expanding and growing revenue through treatment/clinic centers as well as research/clinical trials.......the last is recreational.....Field Trip, Buzz,.....its a small group but they have actual revenue......mushrooms are legal in the netherlands......always do your own DD....
<< Previous
Bullboard Posts
Next >>